BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 10581328)

  • 1. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
    Drummond DC; Meyer O; Hong K; Kirpotin DB; Papahadjopoulos D
    Pharmacol Rev; 1999 Dec; 51(4):691-743. PubMed ID: 10581328
    [No Abstract]   [Full Text] [Related]  

  • 2. Conditions of drug delivery within solid tumors, and noninvasive methods for studies in humans.
    Port RE
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):78-9. PubMed ID: 9147714
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug delivery in cancer using liposomes.
    Dass CR
    Methods Mol Biol; 2008; 437():177-82. PubMed ID: 18369969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotide delivery to tumours using macromolecular carriers.
    Dass CR
    Biotechnol Appl Biochem; 2004 Oct; 40(Pt 2):113-22. PubMed ID: 15070400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomes and cancer therapy.
    Gregoriadis G; Florence AT
    Cancer Cells; 1991 Apr; 3(4):144-6. PubMed ID: 1883687
    [No Abstract]   [Full Text] [Related]  

  • 6. [Influence of the diameter of the drug carriers for accumulation to tumors].
    Murota H; Goto A; Unno K
    Nihon Rinsho; 1989 Jun; 47(6):1363-8. PubMed ID: 2769997
    [No Abstract]   [Full Text] [Related]  

  • 7. Liposomes designed to avoid the reticuloendothelial system.
    Papahadjopoulos D; Gabizon A
    Prog Clin Biol Res; 1990; 343():85-93. PubMed ID: 2198586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and pharmacokinetics of a novel pirarubicin liposome powder.
    Cong W; Liu Q; Chen X; Gao R; Lu J; Wang Y; Luo G
    Drug Dev Ind Pharm; 2010 Oct; 36(10):1186-94. PubMed ID: 20515395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes for drug delivery to mitochondria.
    Boddapati SV; D'Souza GG; Weissig V
    Methods Mol Biol; 2010; 605():295-303. PubMed ID: 20072889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of high molecular weight agents.
    Cassidy J; Newell DR; Wedge SR; Cummings J
    Cancer Surv; 1993; 17():315-41. PubMed ID: 8137346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and use of ceramide nanoliposomes in cancer.
    Watters RJ; Kester M; Tran MA; Loughran TP; Liu X
    Methods Enzymol; 2012; 508():89-108. PubMed ID: 22449922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical mechanisms and methods employed in drug delivery to tumors.
    Besić E
    Acta Pharm; 2007 Sep; 57(3):249-68. PubMed ID: 17878107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Segidrin: a new-type antineoplastic agent].
    Filov VA
    Vopr Onkol; 1994; 40(1-3):3-14. PubMed ID: 7701790
    [No Abstract]   [Full Text] [Related]  

  • 14. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.
    Needham D; Anyarambhatla G; Kong G; Dewhirst MW
    Cancer Res; 2000 Mar; 60(5):1197-201. PubMed ID: 10728674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivascular and antitumor activities of liposome-associated drugs.
    Straubinger RM; Arnold RD; Zhou R; Mazurchuk R; Slack JE
    Anticancer Res; 2004; 24(2A):397-404. PubMed ID: 15152936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cancer with bugs and liposomes: ready, aim, fire.
    Cheong I; Huang X; Thornton K; Diaz LA; Zhou S
    Cancer Res; 2007 Oct; 67(20):9605-8. PubMed ID: 17942887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria].
    Felfoul O; Mohammadi M; Taherkhani S; de Lanauze D; Zhong Xu Y; Lafleur M; Gaboury L; Tabrizian M; Vuong T; Batist G; Beauchemin N; Radzioch D; Martel S
    Med Sci (Paris); 2018 Mar; 34(3):197-199. PubMed ID: 29547100
    [No Abstract]   [Full Text] [Related]  

  • 18. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
    Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
    J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles.
    Shenoy VS; Vijay IK; Murthy RS
    J Pharm Pharmacol; 2005 Apr; 57(4):411-22. PubMed ID: 15831200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted drug delivery.
    Leyland-Jones B
    Semin Oncol; 1993 Feb; 20(1):12-7. PubMed ID: 8475405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.